Jak out of the box: Targeting Bruton's tyrosine kinase, sialic acid-binding immunoglobulin-like lectin-8, and Janus kinase 1 in food allergy.
Ann Allergy Asthma Immunol
; 131(1): 23-28, 2023 07.
Article
em En
| MEDLINE
| ID: mdl-36738782
ABSTRACT
There has been rapid growth in the field of immunoglobulin E-mediated food allergy therapeutics, with 1 US Food and Drug Administration-approved therapy in 2020 and several others in various stages of investigation. Oral immunotherapy is the approach with the longest track record of study and provides desensitization for most individuals undertaking the therapy. However, the therapy must be maintained for continued clinical protection, and adverse effects of the therapy are frequent. There is a need to improve allergen immunotherapy safety and durability and to provide a treatment that can target multiple food allergies. In this review, we discuss novel adjunct therapies that may improve safety, such as omalizumab, Bruton's tyrosine kinase inhibitors, and agonists of sialic acid-binding immunoglobulin-like lectin-8, which suppress hypersensitivity responses. We also discuss approaches that may improve magnitude or durability of the treatment response, such as dupilumab and Janus kinase 1 inhibitors.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácido N-Acetilneuramínico
/
Hipersensibilidade Alimentar
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article